Key facts
- It has raised $10.0M; the latest was Early Stage VC ($10.0M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Farcast
- ·The full record, as it builds
Funding rounds
No funding rounds for Farcast are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Farcast
Developer of a human tumor micro dynamics (HTMD) platform designed for the assessment of tumor response. The platform offers microenvironment characteristics and patient-specific factors to create accurate and precise models, allowing for the identification of effective treatment regimens and ultimately, the personalization of cancer therapy, enabling researchers to predict patient response to treatment with higher accuracy.
- Sector
- Healthcare
- HQ
- Pensacola, FL, United States
- Founded
- 2020
- Employees
- 44
- Website
- farcastbio.com/
- Ownership
- Privately Held (backing)
Farcast doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Farcast shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Farcast in its N-PORT filings yet. We sweep new filings monthly.